Kochi, India—Arjuna Natural Ltd.’s curcumin formulation BCM-95 (Curcugreen) demonstrated new possibilities for managing symptoms associated with osteoarthritis (OA) of the knee in a recently published study, according to a press release.
The study was randomized, open-label, and parallel-arm. It involved 139 participants suffering from OA of the knee, given either 500mg BCM-95 three times daily or 50mg Volteran (diclofenac) twice daily for 28 days. Within two weeks of treatment, the release says, BCM-95 showed an ability to reduce pain and relieve joint stiffness, while also improving daily functions of living and overall quality of life at a level similar to that achieved through the NSAID control. Those on BCM-95 also avoided the side effects of NSAIDs.
Benny Antony, Ph.D., joint managing director of Arjuna, said in the release: “The beneficial results obtained in the study are highly likely due to the combination of curcuminoids and essential oil of turmeric present in our proprietary curcumin formulation with increased curcumin bioavailability. The permeability of curcumin is increased by the turmerone-rich essential oil complex, incurring a sevenfold enhancement of plasma curcumin levels, proven to yield statistically significant clinical benefits.”
BCM-95 is GRAS and is backed by more than 50 scientific publications.